SHERRY BROWN: Open Payments
NPI 1952829475 · JONESBORO, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,445 in 82 payments from 19 companies in 2025. Trend: 2023 $912 · 2024 $1,481 · 2025 $1,445
Food & beverage: $1,445
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 18 | $338 |
| Sumitomo Pharma America, Inc. | 10 | $175 |
| ABBVIE INC. | 11 | $160 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $92 |
| Novo Nordisk Inc | 5 | $90 |
| Phathom Pharmaceuticals, Inc. | 8 | $82 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $77 |
| Otsuka America Pharmaceutical, Inc. | 3 | $74 |
| Lilly USA, LLC | 4 | $64 |
| Novartis Pharmaceuticals Corporation | 2 | $51 |
Products named: AIRSUPRA, GEMTESA, FARXIGA, VOQUEZNA, REXULTI, MOUNJARO, UBRELVY, Ozempic.
Industry payments across AR — which companies pay providers there.
